Investment Thesis
Pharma-Bio Serv exhibits fundamental operational distress with negative operating margins (-4.1%) and declining revenue (-5.3% YoY), indicating the core business is unprofitable. The most critical issue is the severe disconnect between positive accounting earnings and negative operating cash flow (-$390.1K), suggesting the reported net income is not backed by sustainable cash generation. While the balance sheet provides temporary protection with minimal debt and strong liquidity, the company is burning cash operationally and returning minimal capital to shareholders (ROE 0.3%), requiring urgent operational restructuring.
Strengths
- Minimal leverage with zero long-term debt and low debt-to-equity ratio
- Strong liquidity position with current ratio of 4.03x and $5.8M cash reserves
- Positive net income of $32.9K showing some accounting profitability
Risks
- Negative operating margins (-4.1%) indicate core business operations are unprofitable
- Severe cash flow deterioration: negative operating cash flow of -$390.1K despite positive net income signals low-quality earnings and unsustainable profitability
- Declining revenue trend (-5.3% YoY) combined with inability to control costs suggests structural business challenges
- Extremely poor capital efficiency with ROE of 0.3% and ROA of 0.2% indicating minimal shareholder value creation
- Micro-cap OTC trading with limited liquidity and market depth
Key Metrics to Watch
- Operating cash flow trend - critical indicator of whether positive net income is sustainable
- Gross margin stability - monitor if margin compression will worsen profitability
- Cash burn rate and runway - at current -$392.6K FCF, cash reserves deplete in ~14.7 years unless operations improve
- Revenue stabilization - must return to growth to demonstrate business viability
Financial Metrics
Revenue
2.3M
Net Income
32.9K
EPS (Diluted)
$0.00
Free Cash Flow
-392.6K
Total Assets
13.5M
Cash
5.8M
Profitability Ratios
Gross Margin
31.5%
Operating Margin
-4.1%
Net Margin
1.4%
ROE
0.3%
ROA
0.2%
FCF Margin
-17.1%
Balance Sheet & Liquidity
Current Ratio
4.03x
Quick Ratio
4.03x
Debt/Equity
0.00x
Debt/Assets
24.4%
Interest Coverage
-12.87x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T01:51:22.961024 |
Data as of: 2026-01-31 |
Powered by Claude AI